PRESS RELEASES
MediaPress Releases
See our recent news and announcements below. If you have any questions or for media inquiries, please contact info@pyramidbio.com for assistance or see specified media contact details within each release.
Pyramid Biosciences Announces TIME TrialTM Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors
WALTHAM, MA, April 12, 2022 - Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a range of serious diseases, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to strengthen and amplify identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial of Pyramid’s lead oncology program PBI- 200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor (PBI-200-101). [read more...]
Previous Press Releases
Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief Executive Officer
Pyramid Biosciences Expands Precision Oncology Pipeline
Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology
Pyramid Biosciences Announces Leadership Team Expansion
Pyramid Biosciences Secures $28 Million in Funding to Accelerate Clinical Programs